Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
9.1 (USD) • At close November 1, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Corvus Pharmaceuticals, Inc. |
Symbool | CRVS |
Munteenheid | USD |
Prijs | 9.1 |
Beurswaarde | 569,216,830 |
Dividendpercentage | 0% |
52-weken bereik | 1.21 - 9.28 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Richard A. Miller M.D. |
Website | https://www.corvuspharma.com |
An error occurred while fetching data.
Over Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)